Vanda Pharmaceuticals Inc - Company Profile
Powered by 
All the data and insights you need on Vanda Pharmaceuticals Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Vanda Pharmaceuticals Inc Strategy Report
- Understand Vanda Pharmaceuticals Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Business Description
Vanda Pharmaceuticals Inc (Vanda) develops and commercializes novel therapies to address high unmet medical needs for certain central nervous system disorders. The company operates in one reportable segment. Its marketed products include Hetlioz (tasimelteon) and Fanapt (iloperidone).
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
R&D Overview
Vanda’s R&D efforts focus on developing novel therapies to address high unmet medical needs. - Major pipeline products include VLY-686 (Tradipitant), VTR-297, CFTR and VQW-765. In FY2022, the company incurred R&D expense of US$85.8 million, which was 33% of its revenue and grew 13.8% YoY. - Comprises of fifteen method of use patent application and two drug substance patent for Hetlioz; nine method of use patent application and three drug substance patent for Hetlioz IQ; nine method of treatment patent application for Fanapt and other numerous issued patents and patent applications in key markets.
Product Categories
Overview
Fanapt (Iloperidone) is the US FDA approved oral formulation indicated for the treatment of schizophrenia. The company acquired all commercial rights to Fanapt (Iloperidone) in the US and Canada from Novartis Pharma AG. -Fanapt also finds therapeutic applications for the treatment of various other disorders, including major depressive disorder and bipolar depression - Vanda distributes Fanapt in the US, Israel and Mexico.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Overview
Hetlioz (tasimelteon), a US FDA approved melatonin receptor agonist for the treatment of Non-24-hour sleep-wake disorder (Non-24). Hetlioz is commercially launched in Germany and the US. Hetlioz is also indicated for various circadian rhythm disorders. The company is investigating tasimelteon for the treatment of pediatric Non-24, smith-magenis syndrome (SMS), delayed sleep phase disorder and jet lag disorder.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer